Publications [#134194] of Mark W. Dewhirst

Papers Published

1. CA Novotney, RL Page, DW Macy, MW Dewhirst, GK Ogilvie, SJ Withrow, MC McEntee, GL Heidner, SA Allen, DE Thrall, Phase I evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphoma., Journal of veterinary internal medicine / American College of Veterinary Internal Medicine, UNITED STATES, vol. 6 no. 4 , pp. 245-9, ISSN 0891-6640
   (last updated on 2004/03/30)

   Abstract:
   Fifteen previously untreated dogs with histologically confirmed, high-grade multicentric lymphoma were entered into a phase I study to evaluate combined doxorubicin and whole-body hyperthermia (DOX/WBH). Groups of three, four, and eight dogs were treated with whole-body hyperthermia and concurrent doxorubicin at 12 mg/m2, 24 mg/m2 and 30 mg/m2, respectively, after one doxorubicin induction dose at 30 mg/m2. Plateau temperature (42 +/- 0.1 degree C) was maintained for 90 minutes using a radiant heating device. A total of five DOX/WBH treatments per dog were planned, and these were given every 21 days. Treatment-related toxicity was not seen in the 12-mg/m2 doxorubicin dose group. Tumor progression prohibited administration of more than three DOX/WBH treatments to any dog in the 12-mg/m2 group. Premature ventricular contractions developed after the fifth treatment in one of the four dogs treated with 24 mg/m2 of doxorubicin. Two dogs (25%) in the 30-mg/m2 dose group had treatment-related toxicity. One dog experienced acute serious myelosuppression 1 week after the third treatment. This dog received all planned DOX/WBH treatments. Asymptomatic cardiac toxicosis consisting of decreased ejection fraction and fractional shortening developed in the second dog. This dog received only two DOX/WBH treatments. The three dogs treated at 12 mg/m2 had partial responses of short duration (60-83 days). Four dogs treated at 24 mg/m2 had complete responses for 150, 164, 186, and 200 days. Eight dogs treated at 30 mg/m2 had complete responses with a mean and median duration of 241 and 190 days, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

   Keywords:
   Animals • Bone Marrow • Chemotherapy, Adjuvant • Dog Diseases • Dogs • Doxorubicin • Drug Evaluation • Female • Heart • Hyperthermia, Induced • Lymphoma • Male • Treatment Outcome • adverse effects • drug effects • therapeutic use* • therapy • therapy* • veterinary*